Search | IOVS | ARVO Journals

View

Showing 1 – 9 of 9

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

Effects of Omidenepag Isopropyl, a Selective EP2 Receptor Agonist, on Iris Pigmentation

Yoshihiko Esaki; Takazumi Taniguchi; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Hidetoshi Mano; Takeshi Matsugi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3780. doi:

ARVO Annual Meeting Abstract July 2019

Effects of Omidenepag, a Selective EP2 Receptor Agonist on Adipocyte Differentiation

Yasuko Yamamoto; Takazumi Taniguchi; Masahiro Ota; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Takeshi Matsugi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3781. doi:

ARVO Annual Meeting Abstract July 2018

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-induced Ocular Hypertensive Monkeys

Masahiro Fuwa; Carol B Toris; Shan Fan; Takazumi Taniguchi; Masaki Ichikawa; Noriko Odani-Kawabata; Ryo Iwamura; Kenji Yoneda; Takeshi Matsugi; Naveed Kamal Shams; Jin-Zhong Zhang

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2717. doi:

ARVO Annual Meeting Abstract July 2018

Effects of a selective EP2 receptor agonist, omidenepag isopropyl, on eyelash growth in mice

Yoshihiko Esaki; Osamu Katsuta; Takazumi Taniguchi; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Mitsunori Maeda; Hidetoshi Mano; Takeshi Matsugi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2718. doi:

Glaucoma January 2018

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent

PDF

Tomoko Kirihara; Takazumi Taniguchi; Kenzo Yamamura; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Atsushi Shimazaki; Takeshi Matsugi; Naveed Shams; Jin-Zhong Zhang
TAGS: agonists, antihypertensive agents, intraocular pressure, pharmacology, prostaglandins
Invest. Ophthalmol. Vis. Sci.. 2018; 59(1):145-153. doi: https://doi.org/10.1167/iovs.17-22745

ARVO Annual Meeting Abstract June 2017

Pharmacokinetics, Safety and IOP Lowering Profiles of omidenepag isopropyl, a Selective EP2 Agonist in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Makoto Aihara; Fenghe Lu; Hisashi Kawata; Yuki Tanaka; Kenzo Yamamura; Ryo Iwamura; Kenji Yoneda; Noriko Odani; Naveed Shams

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2104. doi:

ARVO Annual Meeting Abstract June 2017

Omidenepag isopropyl, a selective EP2 agonist, shows additive intraocular pressure (IOP)-lowering effects when used concomitantly with existing anti-glaucoma drugs in animal models

Takazumi Taniguchi; Tomoko Kirihara; Miki Takahashi; Ryo Iwamura; Kenji Yoneda; Noriko Odani; Atsushi Shimazaki; Masaki Ichikawa; Jin-Zhong Zhang

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2105. doi:

ARVO Annual Meeting Abstract June 2015

Safety and Efficacy of DE-117, a Selective EP 2 Agonist in a Phase 2a Study

Nnenna Ihekoromadu; Fenghe Lu; Ryo Iwamura; Kenji Yoneda; Noriko Kawabata-Odani; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5708. doi:

ARVO Annual Meeting Abstract June 2015

DE-117, a selective EP2 agonist, lowered intraocular pressure in animal models

Tomoko Kirihara; Ryo Iwamura; Kenji Yoneda; Noriko Kawabata-Odani; Atsushi Shimazaki; Kouichi Kawazu

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5709. doi:

Advertisement